Lojuxta - direct healthcare professional communication (DHPC)

Lomitapide

About

This direct healthcare professional communication (DHPC) contains important information for healthcare professionals prescribing, dispensing or administering the medicine(s). It also includes a communication plan with details of intended recipients and the dissemination date.

Documents

Direct healthcare professional communication (DHPC): Reminder to monitor the liver function of patients treated with Lojuxta and to avoid use in pregnancy

Key facts

• Medicine name:
  Lojuxta
• Active substance:
  Lomitapide
• Therapeutic area (MeSH):
  Hypercholesterolemia
• Procedure number:
  EMEA/H/C/002578/S/0043
• Regulatory outcome:
  Maintenance
• DHPC type:
  Post-authorisation measure
• Human ATC codes:
  C10AX12
• Dissemination date:
  17/02/2021